X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Prochymal (remestemcel-L) is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells. It is being evaluated for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).
Lead Product(s): Remestemcel-L
Therapeutic Area: Immunology Product Name: Prochymal
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
Revascor (rexlemestrocel-L) is an allogeneic preparation of immunoselected and culture-expanded mesenchymal precursor cells. It is being developed for treatment of hypoplastic left heart syndrome in children.
Lead Product(s): Rexlemestrocel-L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Revascor
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Revascor (rexlemestrocel-L) is an allogeneic preparation of immunoselected and culture-expanded mesenchymal precursor cells. It is under phase 1/2 clinical development for the treatment of Hypoplastic Left Heart Syndrome.
Lead Product(s): Rexlemestrocel-L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Revascor
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Revascor (rexlemestrocel-L) is an allogeneic preparation of immunoselected and culture-expanded mesenchymal precursor cells. It is under phase 1/2 clinical development for the treatment of Hypoplastic Left Heart Syndrome.
Lead Product(s): Rexlemestrocel-L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Revascor
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 26, 2023
Details:
The agreement aims to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD).
Lead Product(s): Remestemcel-L
Therapeutic Area: Immunology Product Name: Ryoncil
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BMT CTN
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 21, 2023
Details:
Ryoncil (remestemcel-l) have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved tissues.
Lead Product(s): Remestemcel-L
Therapeutic Area: Immunology Product Name: Ryoncil
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Remestemcel-L have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved tissues.
Lead Product(s): Remestemcel-L
Therapeutic Area: Immunology Product Name: Prochymal
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
The net proceedings will be used to fund the launch and commercialization of the company’s lead product, Prochymal (remestemcel-L), in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).
Lead Product(s): Remestemcel-l
Therapeutic Area: Immunology Product Name: Prochymal
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 25, 2023
Details:
Remestemcel-L have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved tissues.
Lead Product(s): Remestemcel-l
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
Revascor (rexlemestrocel-L) reverses inflammation-related endothelial dysfunction and reduces adverse clinical outcomes across the spectrum of HFrEF patients. It is in development for advanced chronic heart failure and chronic low back pain.
Lead Product(s): Rexlemestrocel-L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Revascor
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
